462 results on '"Lussier, Firoza Z."'
Search Results
2. Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
3. Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts
4. Tau follows principal axes of functional and structural brain organization in Alzheimer’s disease
5. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
6. Insights into the use of biomarkers in clinical trials in Alzheimer's disease
7. APOEε4 potentiates amyloid β effects on longitudinal tau pathology
8. Modeling the progression of neuropsychiatric symptoms in Alzheimer’s disease with PET-based Braak staging
9. 14-3-3 ζ/δ-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
10. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
11. Vascular risk burden is a key player in the early progression of Alzheimer’s disease
12. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
13. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
14. Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
15. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
16. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
17. Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging
18. Microglial activation and tau propagate jointly across Braak stages
19. Sex modulates the role of astrocyte reactivity in preclinical Alzheimer’s disease
20. CSF total tau is more closely associated with synaptic dysfunction than overt neurodegeneration
21. Association of reactive astrogliosis and microglial activation with tau pathology in Alzheimer’s disease
22. Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum
23. Plasma p‐tau and brain‐derived total tau biomarkers predict longitudinal changes in Aβ, tau, and cognition across the AD continuum
24. Neuroinflammation Exacerbates Irritability and Agitation in Alzheimer’s Disease
25. Mapping the effects of functional and structural network reorganization on the tau‐cognition relationship in Alzheimer’s disease
26. Amyloid β‐dependent tau phosphorylation is triggered by reactive astrocytes in preclinical Alzheimer’s disease
27. Plasma biomarkers as stand‐alone tests in the diagnosis of Alzheimer’s disease
28. APOEε4 potentiates the effects of Aβ pathology on the deposition of neurofibrillary tangles via tau phosphorylation
29. Interactions of synaptic and inflammatory biomarkers in Alzheimer’s Disease
30. Assessment of brain oxygen extraction in aging and Alzheimer’s disease with MRI images
31. Amyloid and Tau Predominance Subtyping Identifies CI Patients With Different Clinical Phenotypes
32. Fast accumulators of tau have higher levels of plasma pTau and stronger associations with amyloid in later Braak regions at baseline
33. The impact of young controls in the detection of tau load in cognitively impaired and asymptomatic elderly
34. Microglial activation interacts with amyloid‐β to drive longitudinal tau tangle accumulation and cognitive decline
35. Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction related to cognitive impairment
36. Potential utility of using both APOEε4 and Aβ positivity to enrich clinical trials of tau‐targeting therapies
37. Sex impacts the association of plasma Glial Fibrillary Acidic Protein with neurodegeneration in Alzheimer’s disease
38. Plasma biomarkers of tau for the differentiation between slow and fast tau‐PET accumulators
39. Increased Genetic Risk for ADHD Potentiates Cognitive Impairment and Brain Hypometabolism in Alzheimer’s Disease Patients
40. Microglial Activation Contributes to Neuropsychiatric Dysfunction in Alzheimer’s Disease
41. Astrocyte reactivity potentiates longitudinal tau tangle accumulation in cognitively unimpaired individuals
42. Synapse dysfunction and astrocyte reactivity are associated independently of amyloid‐β and tau pathologies
43. Plasma p‐tau181 and nfl as surrogates biomarkers in clinical trials targeting preclinical stage of Alzheimer’s disease
44. Employing transfer learning to optimize deep learning models for Alzheimer’s disease classification using two tau PET tracers
45. Independent associations of plasma GFAP with amyloid‐β and tau in Alzheimer’s disease
46. Plasma p‐tau231 and p‐tau217 provides information on tau tangle deposition in symptomatic Alzheimer’s disease individuals
47. Assessment of quantitative susceptibility mapping (QSM) and oxygen extraction fraction (OEF) in the spectrum of Alzheimer’s disease clinical presentations
48. Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
49. 14-3-3 $$\upzeta /\updelta$$-reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
50. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.